C-reactive protein in Crohn's disease: how informative is it? (Q38196441)

30 August 2017

1 reference

title

C-reactive protein in Crohn's disease: how informative is it? (English)

1 reference

30 August 2017

1 reference

1

1 reference

30 August 2017

Paula Sousa

2

1 reference

PubMed ID

24635486

30 August 2017

Paula Ministro

series ordinal

3

1 reference

30 August 2017

17 March 2014

1 reference

Expert Review of Gastroenterology & Hepatology

30 August 2017

1 reference

30 August 2017

8

1 reference

30 August 2017

4

1 reference

30 August 2017

393-408

1 reference

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD : I. DISTRIBUTION OF THE REACTIVE PROTEIN IN PATIENTS' SERA AND THE EFFECT OF CALCIUM ON THE FLOCCULATION REACTION WITH C POLYSACCHARIDE OF PNEUMOCOCCUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD : II. ISOLATION AND PROPERTIES OF THE REACTIVE PROTEIN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

The physiological structure of human C-reactive protein and its complex with phosphocholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Pentraxins: structure, function, and role in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

The liver as the site of C-reactive protein formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein: history and revival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein in rheumatology: biology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein as a marker for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Human C-reactive protein: expression, structure, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein at the interface between innate immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein: ligands, receptors and role in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Regulation of complement activation by C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

What is the role of serological markers in IBD? Pediatric and adult data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Indications for investigation of chronic gastrointestinal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

The role of fecal calprotectin in investigating inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Differing acute phase responses in Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

High-sensitivity C-reactive protein in paediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Role of biomarkers in the diagnosis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Microbiota separation and C-reactive protein elevation in treatment-naïve pediatric granulomatous Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein and monitoring the activity of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Acute-phase proteins and other systemic responses to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Serum calprotectin as a biomarker for Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

What predicts mucosal inflammation in Crohn's disease patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein reassessed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Mucosal healing in Crohn's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Predicting relapse in Crohn's disease: a biopsychosocial model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2014.893821

10.1586/17474124.2014.893821

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24635486